1,359 results match your criteria: "Albert Schweitzer Hospital[Affiliation]"
Cardiol Res
December 2024
Department of Forensic Medicine, Imam Khomeini Hospital, Tehran, Iran.
Background: This study evaluated the safety and efficacy of BioMime sirolimus-eluting stent (SES) system, with an ultra-low strut thickness (65 µm), in real-world all-comers population with coronary artery stenosis (CAD).
Methods: This was a post-marketing, multicenter, single-arm, observational clinical registry among patients undergoing intervention for CAD. Patients were clinically followed up at 1, 9, 12, and 24 months after the index percutaneous coronary intervention.
JAMA Neurol
December 2024
Department of Neurology, Erasmus MC University Medical Center, Rotterdam, the Netherlands.
Importance: Efficient care processes are crucial to minimize treatment delays and improve outcome after endovascular thrombectomy (EVT) in patients with ischemic stroke. A potential means to improve care processes is performance feedback.
Objective: To evaluate the effect of performance feedback to hospitals on treatment times for EVT.
EClinicalMedicine
December 2024
Department of Obstetrics and Gynaecology, Amsterdam UMC Location University of Amsterdam, Meibergdreef 9, Amsterdam, the Netherlands.
Background: Previous spontaneous preterm birth (sPTB) is a strong risk indicator for recurrent preterm birth (PTB). Cervical cerclage is an accepted intervention to prevent recurrent PTB in high risk patients. Cervical pessary might be a less invasive alternative.
View Article and Find Full Text PDFEndoscopy
December 2024
Department of Gastroenterology and Hepatology, University Medical Centre Utrecht, Utrecht, Netherlands.
Background And Study Aims: Piecemeal EMR of large (≥20mm) non-pedunculated colorectal polyps (LNPCPs) is succeeded by a 6-month surveillance endoscopy to evaluate the post-EMR scar for recurrence. Data from expert centers suggest that routine tattoo placement and scar biopsies can be omitted, but data from community hospitals are lacking.
Patients And Methods: In a post-hoc analysis of the STAR-LNPCP study (NTR7477), containing prospective data on 6-month post-pEMR scar assessments in 30 Dutch community hospitals (October 2019 to May 2022), the agreement between optical assessment and histological confirmation by routine biopsies was evaluated.
N Engl J Med
December 2024
From Alexandra General Hospital, National and Kapodistrian University of Athens, Athens (M.A.D.); Levine Cancer Institute, Atrium Health Wake Forest University School of Medicine, Charlotte, NC (P.M.V.); Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo (F.S.); Tel-Aviv Sourasky (Ichilov) Medical Center and Tel Aviv University, Tel Aviv, Israel (Y.C.C.); Clínica Medica São Germano, São Paulo (V.H.); Cross Cancer Institute, University of Alberta, Edmonton, Canada (I. Sandhu); Kent and Canterbury Hospital, Canterbury, United Kingdom (J.L.); Perth Blood Institute, Murdoch University, Perth, WA, Australia (R.I.B.); Japanese Red Cross Medical Center, Tokyo (K.S.); Ogaki Municipal Hospital, Ogaki City, Japan (H.K.); Albert Schweitzer Hospital, Dordrecht, the Netherlands (M.-D.L.); Ankara University, Ankara, Turkey (M.B.); Washington University School of Medicine, St. Louis (K.S.-G.); Institut Català d'Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona (A.O.); South Pest Central Hospital, National Institute for Hematology and Infectious Diseases, Budapest, Hungary (G.M.); Hospital Alemán, Buenos Aires (G.G.); Jessa Hospital, Hasselt, Belgium (K.T.); Charles University and General Hospital, Prague, Czech Republic (I. Spicka); Rigshospitalet, University of Copenhagen, Copenhagen (A.K.M.); SSD Clinical Trials in Oncol-ematologia e Mieloma Multiplo, AOU Città della Salute e della Scienza di Torino, Turin, Italy (S.B.); Medical Unit Hematology, Karolinska University Hospital, Stockholm (K.U.); Institute of Hematology and Transfusion Medicine, Warsaw, Poland (B.P.); Knight Cancer Institute, Oregon Health and Science University, Portland (E.M.); University of Washington and Fred Hutchinson Cancer Center, Seattle (A.J.C.); University Hospital Hôtel-Dieu, Nantes, France (P.M.); University Hospital of Salamanca, IBSAL, and Cancer Research Center, IBMCC, Salamanca, Spain (M.-V.M.); GMMG Study Group at University Hospital Heidelberg, Internal Medicine V, Heidelberg, Germany (H.G.); Genmab US, Plainsboro, NJ (T.A.); Janssen Research and Development, Shanghai, China (L.S., L.L.); Janssen Scientific Affairs, Horsham, PA (A.C.); Janssen Research and Development, Raritan, NJ (E.G.K., R.M.D.); Janssen Research and Development, Beerse, Belgium (E.R.); Janssen Research and Development, Spring House, PA (R.C.); and Mayo Clinic, Rochester, MN (S.V.R.).
Background: Daratumumab, an anti-CD38 monoclonal antibody, has been approved for the treatment of multiple myeloma. Data are needed regarding the use of daratumumab for high-risk smoldering multiple myeloma, a precursor disease of active multiple myeloma for which no treatments have been approved.
Methods: In this phase 3 trial, we randomly assigned patients with high-risk smoldering multiple myeloma to receive either subcutaneous daratumumab monotherapy or active monitoring.
JAMA Neurol
December 2024
Multiple Sclerosis Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam University Medical Center location VUmc, Amsterdam, the Netherlands.
Importance: Increasing numbers of people with multiple sclerosis (MS) use disease-modifying therapy (DMT). Long-term stable disease while taking such medications provides a rationale for considering DMT discontinuation given patient burden, costs, and potential adverse effects of immunomodulating therapy.
Objective: To investigate whether first-line DMT can be safely discontinued in patients with long-term stable MS.
Clin Transplant
December 2024
Erasmus MC Transplant Institute, Rotterdam, The Netherlands.
Background: Alemtuzumab can be an alternative to rabbit anti-thymocyte globulin (rATG) to treat severe or glucocorticoid-resistant acute T cell-mediated kidney transplant rejection (TCMR). Yet, there are few reports in which these two treatments are evaluated let alone, compared. This study describes the real-world clinical experience of both therapies and compares their efficacy and toxicity.
View Article and Find Full Text PDFColorectal Dis
December 2024
Department of Surgery, Ikazia Hospital, Rotterdam, The Netherlands.
Aliment Pharmacol Ther
December 2024
Department of Gastroenterology and Hepatology, Erasmus University Medical Centre, Rotterdam, The Netherlands.
Case Rep Womens Health
December 2024
Department of Obstetrics and Gynaecology, Albert Schweitzer hospital, Albert Schweitzerplaats 25, 3318 AT Dordrecht, the Netherlands.
This case report examines caesarean scar pregnancy, a rare but significant complication associated with increasing global caesarean rates. It explores diagnostic challenges, therapeutic interventions, and the importance of a multidisciplinary approach. This report details the case of a patient at 13 + 4 weeks of amenorrhea presenting with severe abdominal pain, diagnosed with caesarean scar pregnancy and scar dehiscence causing major haemorrhage.
View Article and Find Full Text PDFColorectal Dis
December 2024
Department of Surgery, Ikazia Hospital, Rotterdam, the Netherlands.
J Mol Diagn
November 2024
Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, the Netherlands. Electronic address:
Eur J Cancer
January 2025
Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Netherlands.
Br J Surg
November 2024
Department of Surgery, Albert Schweitzer Hospital, Dordrecht, the Netherlands.
Ann Diagn Pathol
February 2025
Department of Pathology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands. Electronic address:
Fundamental and translational research in ovarian cancer aims to enhance understanding of disease mechanisms and improve treatment and survival outcomes. To support this, we established the Dutch multicenter, interdisciplinary Archipelago of Ovarian Cancer Research (AOCR) infrastructure, which includes a nationwide biobank. In this study, we share our experiences in establishing the infrastructure, offer guidance for similar initiatives, and evaluate the AOCR patient cohort.
View Article and Find Full Text PDFArch Dermatol Res
November 2024
Department of Dermatology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Blood
November 2024
Amsterdam UMC. Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, Netherlands.
Hemasphere
November 2024
Department of Research and Development Netherlands Comprehensive Cancer Organisation (IKNL) Utrecht The Netherlands.
Chronic lymphocytic leukemia (CLL) manifests heterogeneously with varying outcomes. This population-based study examined causes of death (CODs), as registered by the physician who established the death, among 20,588 CLL patients diagnosed in the Netherlands between 1996 and 2020. Utilizing cause-specific flexible parametric survival models, we estimated cause-specific hazard ratios (HRs) and cumulative incidences of death due to CLL, solid malignancies, other hematological malignancies, infections, and other causes.
View Article and Find Full Text PDFEur Heart J Cardiovasc Imaging
November 2024
Department of Cardiology, Radboud University Medical Center, Nijmegen, the Netherlands.
Rheumatology (Oxford)
November 2024
Department of Rheumatology, Erasmus MC, Rotterdam, The Netherlands.
Pharmacoecon Open
October 2024
Department of Cardiology, Thoraxcentrum Twente, Medisch Spectrum Twente, Koningsplein 1, 7512 KZ, Enschede, The Netherlands.
Background And Objective: Evidence on health economic outcomes for percutaneous coronary intervention (PCI) comparing different contemporary drug-eluting stents (DES) with each other is scarce, as most previous randomised DES trials did not assess such aspects. This prespecified health economic evaluation of the Comparison of Biodegradable Polymer and Durable Polymer Drug-Eluting Stents in an All Comers Population (BIO-RESORT) trial aimed to compare at 3-year follow-up both health effects and costs of PCI with one of three new-generation drug-eluting stents (DES) in patients with obstructive coronary artery disease.
Methods: The randomised BIO-RESORT trial assessed in 3514 patients the ultrathin-strut biodegradable polymer Orsiro sirolimus-eluting stent (SES) and very-thin-strut Synergy everolimus-eluting (EES) stent versus the thin-strut durable polymer Resolute Integrity zotarolimus-eluting stent (ZES).
RMD Open
October 2024
Department of Rheumatology, Erasmus MC, Rotterdam, Zuid-Holland, The Netherlands.
Objectives: The widespread adoption of wearables, for example, smartphones and smartwatches in the daily lives of the general population, allows passive monitoring of physiological and behavioural data in the real world. This qualitative study explores the perspective of psoriatic arthritis (PsA) patients towards these so-called digital biomarkers (dBMs).
Methods: As part of a Design Thinking approach, six focus groups were conducted involving 27 PsA patients.
JAMA Neurol
December 2024
Department of Neurology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
RMD Open
October 2024
Department of Rheumatology, Erasmus MC, Rotterdam, The Netherlands.
Otolaryngol Pol
October 2024
Department of Otolaryngology and Laryngological Oncology, Poznan University of Medical Sciences, Poznan, Poland.